Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 298
- Registration Number
- NCT00132301
- Locations
- 🇺🇸
G.V. (Sonny) Montgomery VA Medical Center, Jackson, Jackson, Mississippi, United States
🇺🇸VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States
🇺🇸VA Medical Center, Minneapolis, Minneapolis, Minnesota, United States
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT00121199
- Locations
- 🇺🇸
SWOG, Portland, Oregon, United States
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
- Conditions
- Interventions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 183
- Registration Number
- NCT00119678
- Locations
- 🇺🇸
8737 Beverly Blvd., Los Angeles, California, United States
🇺🇸Office Of Geoffrey S. Dolan, Md, Long Beach, California, United States
🇺🇸Kentuckiana Center For Better Bone And Joint Health, Louisville, Kentucky, United States
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 524
- Registration Number
- NCT00118209
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States
🇺🇸Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States
High-dose Prednisone in Duchenne Muscular Dystrophy
- First Posted Date
- 2005-05-13
- Last Posted Date
- 2011-10-27
- Target Recruit Count
- 64
- Registration Number
- NCT00110669
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1050
- Registration Number
- NCT00110214
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Cancer and Leukemia Group B, Chicago, Illinois, United States
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicinDrug: dexamethasoneDrug: doxorubicinDrug: leucovorinDrug: mercaptopurineDrug: methotrexateDrug: mitoxantroneDrug: AsparaginaseDrug: prednisoneDrug: thioguanineDrug: vincristineRadiation: radiation therapyDrug: allopurinolDrug: bactrim
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 79
- Registration Number
- NCT00109837
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Minor and James Medical, PLLC, Seattle, Washington, United States
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT00110006
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 86
- Registration Number
- NCT00107380
- Locations
- 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States
🇺🇸Northern Rockies Radiation Oncology Center, Billings, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.